CIK 0000949858 · Non-accelerated filer<br>Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Ticker
- ACHV
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 954343413
- Phone
- 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $175,177
- in 1 filing
Net −$175,177. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-04 | Stewart Richard Alistair Chieve Executive Officer | Grant or award · Performance Restricted Stock Unit | −157,500 | 0 | ||
| 2025-09-04 | Wan Jerry Principal Accounting Officer | Option exercise | +34,100 | 46,764 | ||
| 2025-09-04 | Wan Jerry Principal Accounting Officer | Sale | −14,070 | $2.77 | $39K | 32,694 |
| 2025-09-04 | Wan Jerry Principal Accounting Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −24,500 | 0 | ||
| 2025-09-04 | Wan Jerry Principal Accounting Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −9,600 | 38,400 | ||
| 2025-09-04 | KING THOMAS BRAXTON Director | Option exercise | +455,000 | 455,000 | ||
| 2025-09-04 | KING THOMAS BRAXTON Director | Sale | −139,858 | $2.77 | $387K | 315,142 |
| 2025-09-04 | KING THOMAS BRAXTON Director | Option exercise · Performance Restricted Stock Unit (PRSU) | −455,000 | 0 | ||
| 2025-09-04 | JACOBS CINDY President & CMO | Option exercise | +110,000 | 143,214 | ||
| 2025-09-04 | JACOBS CINDY President & CMO | Sale | −27,629 | $2.77 | $77K | 115,585 |
| 2025-09-04 | JACOBS CINDY President & CMO | Option exercise · Performance Restricted Stock Unit (PRSU) | −84,000 | 0 | ||
| 2025-09-04 | JACOBS CINDY President & CMO | Option exercise · Performance Restricted Stock Unit (PRSU) | −26,000 | 104,000 | ||
| 2025-09-04 | Xinos Jaime Chief Commercial Officer | Option exercise | +69,000 | 95,286 | ||
| 2025-09-04 | Xinos Jaime Chief Commercial Officer | Sale | −20,854 | $2.77 | $58K | 74,432 |
| 2025-09-04 | Xinos Jaime Chief Commercial Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −49,000 | 0 | ||
| 2025-09-04 | Xinos Jaime Chief Commercial Officer | Option exercise · Performance Restricted Stock Unit (PRSU) | −20,000 | 80,000 | ||
| 2025-06-06 | Slaoui Kristen B. Director | Grant or award · Stock Option (right to buy) | +31,500 | 31,500 | ||
| 2025-06-06 | Phelan Nancy R. Director | Grant or award · Stock Option (right to buy) | +31,500 | 31,500 | ||
| 2025-06-06 | Sellig Thomas Director | Grant or award · Stock Option (right to buy) | +31,500 | 31,500 | ||
| 2025-06-06 | Martell Bridget A Director | Grant or award · Stock Option (right to buy) | +31,500 | 31,500 |
Page 3 of 36 · 715 trades